| In Vitro |
DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation[1]. DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability inMM cells[1]. DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death[1]. DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells[1]. DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells[1]. DCZ0415 has IC50s of 1.0–10 μM in CalcuSyn in MM cell lines[1]. DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells[1]. Cell Proliferation Assay[1] Cell Line: Multiple myeloma (MM) cells Concentration: 10, 20 μM Incubation Time: 72 hours Result: Showed a significant decrease in colony formation, indicating it inhibits cell proliferation. Cell Viability Assay[1] Cell Line: MM cells Concentration: 1.25, 2.5, 5, 10, 20, 40 μM Incubation Time: 72 hours Result: Induced a significant dose-dependent decrease of viability. Apoptosis Analysis[1] Cell Line: MM cells Concentration: 10, 20 μM Incubation Time: 24, 48, 72 hours Result: Showed a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death. Cell Cycle Analysis[1] Cell Line: MM cells Concentration: 10 and 20 μM Incubation Time: 24 hours Result: Induced a significant accumulation in G0/G1 MM cells. Western Blot Analysis[1] Cell Line: MM cells Concentration: 10 μM Incubation Time: 48 hours Result: Decreased the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.
|
